vs
BYLINE BANCORP, INC.（BY）与PUMA BIOTECHNOLOGY, INC.（PBYI）财务数据对比。点击上方公司名可切换其他公司
BYLINE BANCORP, INC.的季度营收约是PUMA BIOTECHNOLOGY, INC.的1.5倍（$112.4M vs $75.5M），PUMA BIOTECHNOLOGY, INC.同比增速更快（27.7% vs 9.0%），过去两年PUMA BIOTECHNOLOGY, INC.的营收复合增速更高（31.3% vs 6.4%）
Byline Bank是总部位于美国伊利诺伊州芝加哥的银行，为银行控股公司Byline Bancorp, Inc.的核心子公司，同时是全美SBA 7(a)贷款项目的第四大放贷机构，为客户提供专业的银行及融资相关服务。
彪马生物技术是一家公开上市的生物制药企业，总部位于美国加利福尼亚州洛杉矶，专注于创新药物研发相关业务，在生物制药领域开展研发与商业化运营。
BY vs PBYI — 直观对比
营收规模更大
BY
是对方的1.5倍
$75.5M
营收增速更快
PBYI
高出18.7%
9.0%
两年增速更快
PBYI
近两年复合增速
6.4%
损益表 — Q1 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $112.4M | $75.5M |
| 净利润 | $37.6M | — |
| 毛利率 | — | 69.3% |
| 营业利润率 | — | 22.7% |
| 净利率 | 33.4% | — |
| 营收同比 | 9.0% | 27.7% |
| 净利润同比 | 33.0% | — |
| 每股收益（稀释后） | $0.83 | $0.26 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收BYPBYI
| Q1 26 | $112.4M | — | ||
| Q4 25 | $117.0M | $75.5M | ||
| Q3 25 | $115.7M | $54.5M | ||
| Q2 25 | $110.5M | $52.4M | ||
| Q1 25 | $103.1M | $46.0M | ||
| Q4 24 | $104.7M | $59.1M | ||
| Q3 24 | $101.8M | $80.5M | ||
| Q2 24 | $99.4M | $47.1M |
净利润BYPBYI
| Q1 26 | $37.6M | — | ||
| Q4 25 | $34.5M | — | ||
| Q3 25 | $37.2M | $8.8M | ||
| Q2 25 | $30.1M | $5.9M | ||
| Q1 25 | $28.2M | $3.0M | ||
| Q4 24 | $30.3M | — | ||
| Q3 24 | $30.3M | $20.3M | ||
| Q2 24 | $29.7M | $-4.5M |
毛利率BYPBYI
| Q1 26 | — | — | ||
| Q4 25 | — | 69.3% | ||
| Q3 25 | — | 77.7% | ||
| Q2 25 | — | 76.5% | ||
| Q1 25 | — | 77.1% | ||
| Q4 24 | — | 76.4% | ||
| Q3 24 | — | 63.9% | ||
| Q2 24 | — | 77.4% |
营业利润率BYPBYI
| Q1 26 | — | — | ||
| Q4 25 | 40.1% | 22.7% | ||
| Q3 25 | 43.1% | 17.6% | ||
| Q2 25 | 35.2% | 12.7% | ||
| Q1 25 | 36.4% | 8.7% | ||
| Q4 24 | 38.6% | 22.6% | ||
| Q3 24 | 39.3% | 27.4% | ||
| Q2 24 | 40.4% | -4.6% |
净利率BYPBYI
| Q1 26 | 33.4% | — | ||
| Q4 25 | 34.1% | — | ||
| Q3 25 | 32.1% | 16.2% | ||
| Q2 25 | 27.2% | 11.2% | ||
| Q1 25 | 27.4% | 6.5% | ||
| Q4 24 | 34.3% | — | ||
| Q3 24 | 29.8% | 25.2% | ||
| Q2 24 | 29.9% | -9.6% |
每股收益（稀释后）BYPBYI
| Q1 26 | $0.83 | — | ||
| Q4 25 | $0.77 | $0.26 | ||
| Q3 25 | $0.82 | $0.17 | ||
| Q2 25 | $0.66 | $0.12 | ||
| Q1 25 | $0.64 | $0.06 | ||
| Q4 24 | $0.68 | $0.40 | ||
| Q3 24 | $0.69 | $0.41 | ||
| Q2 24 | $0.68 | $-0.09 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $198.4M | $97.5M |
| 总债务越低越好 | — | $22.7M |
| 股东权益账面价值 | $1.3B | $130.3M |
| 总资产 | $9.9B | $216.3M |
| 负债/权益比越低杠杆越低 | — | 0.17× |
8季度趋势，按日历期对齐
现金及短期投资BYPBYI
| Q1 26 | $198.4M | — | ||
| Q4 25 | $149.1M | $97.5M | ||
| Q3 25 | $259.0M | $94.4M | ||
| Q2 25 | $218.3M | $96.0M | ||
| Q1 25 | $421.3M | $93.2M | ||
| Q4 24 | $563.1M | $101.0M | ||
| Q3 24 | $452.6M | $96.7M | ||
| Q2 24 | $730.5M | $96.8M |
总债务BYPBYI
| Q1 26 | — | — | ||
| Q4 25 | — | $22.7M | ||
| Q3 25 | — | $34.0M | ||
| Q2 25 | — | $45.3M | ||
| Q1 25 | — | $56.7M | ||
| Q4 24 | — | $68.0M | ||
| Q3 24 | — | $79.3M | ||
| Q2 24 | — | $90.7M |
股东权益BYPBYI
| Q1 26 | $1.3B | — | ||
| Q4 25 | $1.3B | $130.3M | ||
| Q3 25 | $1.2B | $115.3M | ||
| Q2 25 | $1.2B | $104.7M | ||
| Q1 25 | $1.1B | $97.1M | ||
| Q4 24 | $1.1B | $92.1M | ||
| Q3 24 | $1.1B | $71.1M | ||
| Q2 24 | $1.0B | $48.5M |
总资产BYPBYI
| Q1 26 | $9.9B | — | ||
| Q4 25 | $9.7B | $216.3M | ||
| Q3 25 | $9.8B | $202.9M | ||
| Q2 25 | $9.7B | $194.9M | ||
| Q1 25 | $9.6B | $196.2M | ||
| Q4 24 | $9.5B | $213.3M | ||
| Q3 24 | $9.4B | $220.7M | ||
| Q2 24 | $9.6B | $205.0M |
负债/权益比BYPBYI
| Q1 26 | — | — | ||
| Q4 25 | — | 0.17× | ||
| Q3 25 | — | 0.30× | ||
| Q2 25 | — | 0.43× | ||
| Q1 25 | — | 0.58× | ||
| Q4 24 | — | 0.74× | ||
| Q3 24 | — | 1.12× | ||
| Q2 24 | — | 1.87× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | — | $14.4M |
| 自由现金流经营现金流 - 资本支出 | — | $14.4M |
| 自由现金流率自由现金流/营收 | — | 19.1% |
| 资本支出强度资本支出/营收 | — | 0.0% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | — | $41.7M |
8季度趋势，按日历期对齐
经营现金流BYPBYI
| Q1 26 | — | — | ||
| Q4 25 | $140.3M | $14.4M | ||
| Q3 25 | $38.3M | $9.7M | ||
| Q2 25 | $16.3M | $14.1M | ||
| Q1 25 | $27.1M | $3.6M | ||
| Q4 24 | $175.2M | $15.6M | ||
| Q3 24 | $19.8M | $11.0M | ||
| Q2 24 | $40.1M | $1.0M |
自由现金流BYPBYI
| Q1 26 | — | — | ||
| Q4 25 | $136.3M | $14.4M | ||
| Q3 25 | $38.0M | $9.7M | ||
| Q2 25 | $15.2M | $14.1M | ||
| Q1 25 | $25.0M | $3.6M | ||
| Q4 24 | $171.2M | $15.6M | ||
| Q3 24 | $19.1M | $11.0M | ||
| Q2 24 | $39.4M | $1.0M |
自由现金流率BYPBYI
| Q1 26 | — | — | ||
| Q4 25 | 116.5% | 19.1% | ||
| Q3 25 | 32.8% | 17.7% | ||
| Q2 25 | 13.7% | 26.8% | ||
| Q1 25 | 24.3% | 7.7% | ||
| Q4 24 | 163.5% | 26.4% | ||
| Q3 24 | 18.8% | 13.7% | ||
| Q2 24 | 39.7% | 2.1% |
资本支出强度BYPBYI
| Q1 26 | — | — | ||
| Q4 25 | 3.4% | 0.0% | ||
| Q3 25 | 0.3% | 0.0% | ||
| Q2 25 | 1.0% | 0.0% | ||
| Q1 25 | 2.0% | 0.1% | ||
| Q4 24 | 3.8% | 0.0% | ||
| Q3 24 | 0.6% | 0.0% | ||
| Q2 24 | 0.7% | 0.0% |
现金转化率BYPBYI
| Q1 26 | — | — | ||
| Q4 25 | 4.06× | — | ||
| Q3 25 | 1.03× | 1.10× | ||
| Q2 25 | 0.54× | 2.41× | ||
| Q1 25 | 0.96× | 1.21× | ||
| Q4 24 | 5.78× | — | ||
| Q3 24 | 0.65× | 0.54× | ||
| Q2 24 | 1.35× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
